Who needs M&A? Alexion's 2Q Soliris sales beat consensus
This article was originally published in Scrip
Executive Summary
Alexion Pharmaceuticals executives deftly evaded questions during a second quarter earnings conference call regarding rumors that the ultra-rare disease specialist is on the verge of acquisition by a big pharma company.